In a significant legal development, Labaton Keller Sucharow LLP has launched a securities class action lawsuit against Baxter International, Inc. and several of its executives. This lawsuit is filed on behalf of the Electrical Workers Pension Fund, Local 103, I.B.E.W., and it targets alleged misstatements made by the company regarding the safety and efficacy of its recently launched medical device, the Novum IQ Large Volume Pump (Novum LVP). The case is officially titled *Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc.*, and has been registered in the Northern District of Illinois under the case number 25-cv-12672.
### Allegations of Misleading Investors
The class action asserts that Baxter misled investors over an extended period, specifically from February 23, 2022, to July 30, 2025. It claims that during this timeframe, the company failed to adequately disclose critical information concerning the Novum LVP, including systemic defects that could lead to severe patient risks. Reports suggest that the device suffered from malfunctions such as underinfusion, overinfusion, and total failure to deliver necessary fluids, which could potentially result in serious harm or even fatalities. The lawsuit contends that Baxter was aware of these issues prior to their public disclosure and that they took insufficient corrective measures to address them.
### Timeline of Events
Concerns surrounding the safety of the Novum LVP began to surface publicly following an exposé by a Missouri news outlet on April 7, 2025, which cited information from a whistleblower. Shortly thereafter, Baxter issued a warning letter to customers on April 24, 2025, highlighting potential risks associated with underinfusion but only acknowledging one serious injury linked to the device at that time. The situation escalated on July 14, 2025, when the company issued a second warning that not only reiterated the underinfusion risks but also introduced the danger of overinfusion, revealing that it had received reports of 79 serious injuries and two patient deaths associated with the pump.
The extent of the alleged misconduct became clear on July 31, 2025, when Baxter announced a voluntary and temporary halt on shipments and installations of the Novum LVP, leading to a drastic stock drop of 22.4%, closing at $21.76. This announcement has prompted the filing of the class action, which seeks to represent all individuals and entities that acquired Baxter common stock during the specified class period.
### Next Steps for Affected Investors
Investors who purchased Baxter stock during the class period and believe they have suffered damages are encouraged to consider their options in this lawsuit. They may seek to be appointed as Lead Plaintiff, with the deadline for filing such motions set for December 15, 2025. However, it is crucial to note that it is not necessary to seek this appointment to participate in any potential recovery for the class. Affected parties may consult with legal counsel of their choice to discuss their involvement in the case. For additional inquiries, interested parties can reach out to Connor C. Boehme, Esq. of Labaton Keller Sucharow LLP, via phone or email.
With a notable history in securities litigation, Labaton Keller Sucharow LLP represents a wide array of pension funds and is recognized for its extensive experience in the field. Their commitment to holding corporations accountable for their actions remains evident as they pursue this case against Baxter International. Further information about this class action can be found through the firm’s website and legal resources.
Related
